Pharmaceutical - Financial, Immunologicals

Filter

Current filters:

FinancialImmunologicals

Popular Filters

Merck Serono on track with pharma strategy

Merck Serono on track with pharma strategy

18-09-2014

Germany’s Merck KGaA says that its biopharmaceutical division - Merck Serono - is well on track with…

ataciceptBiosimilarsFinancialGermanyImmunologicalsMerck KGaAMerck SeronoOncologyPharmaceuticalResearchTH-302

Funding restrictions for rituximab and eltrombopag widened in New Zealand

Funding restrictions for rituximab and eltrombopag widened in New Zealand

20-02-2014

New Zealand’s Pharmaceutical Management Agency PHARMAC has announced the approval of proposals to widen…

Asia-PacificeltrombopagFinancialGlaxoSmithKlineHealthcareImmunologicalsNew ZealandPharmaceuticalrituximabRoche

IVO portfolio company Circassia plans to float on LSE

06-02-2014

The UK’s Imperial Innovations Group says that its largest portfolio company Circassia, has today announced…

Allergy TherapeuticsCircassiaFinancialImmunologicalsPharmaceutical

ALK’s 2013 annual report shows profit down but sales steady

ALK’s 2013 annual report shows profit down but sales steady

05-02-2014

Denmark-based allergy specialist ALK Abello (ALKB: DC) has released its annual report for 2013 recording…

ALK AbelloDenmarkFinancialImmunologicalsPharmaceutical

Medigene’s buy of Trianta is “lucrative move” say analysts

31-01-2014

Medigene’s 4 million euro ($5.5 million) purchase of fellow German company Trianta Immunotherapies…

FinancialImmunologicalsMedigeneMergers & AcquisitionsOncologyPharmaceuticalTrianta ImmunotherapiesUSA

Merck’s Allergopharma to invest 40 million euros in production facility

Merck’s Allergopharma to invest 40 million euros in production facility

12-12-2013

Germany’s Merck KGaA has broken ground on a new production facility for its Allergopharma unit in Reinbek…

AllergopharmaFinancialImmunologicalsMerck KGaAPharmaceuticalProduction

Stallergenes report growth in third quarter results

22-10-2013

French allergy specialists Stallergenes has released its third quarter results showing revenue growth…

EuropeFinancialImmunologicalsOralairPharmaceuticalStallergenes

Pfizer legacy company agrees near half billion dollar settlement with DoJ

31-07-2013

Wyeth Pharmaceuticals, a US pharma rival acquired by US behemoth Pfizer (NYSE:PFE) in 2009, has agreed…

FinancialImmunologicalsLegalMarkets & MarketingNorth AmericaPfizerPharmaceuticalRapamuneWyeth

Merck & Co submits ragweed AIT BLA to the FDA

11-03-2013

US pharma giant Merck & Co (NYSE: MRK) has submitted a Biologics License Application (BLA) to the US…

ALK AbelloFinancialImmunologicalsMerck & CoNorth AmericaPharmaceuticalRegulation

Novartis/Vectura's QVA149 is filed as a treatment for COPD in Europe; Certican EU approval

26-10-2012

The UK's Vectura Group (LSE: VEC) confirmed that its partner, Swiss drug giant Novartis (NOVN: VX) has…

CerticanEuropeFinancialImmunologicalsNovartisPharmaceuticalQVA149RegulationResearchRespiratory and PulmonaryVectura

Ablynx earns milestone from Merck Serono

13-12-2011

Belgium’s Ablynx (Euronext Brussels: ABLX) says it will earn a 1 million-euro ($1.3 million) from…

AblynxBiotechnologyFinancialImmunologicalsMerck KGaAMerck SeronoPharmaceuticalResearch

Parexel

Parexel

Back to top